Related Experiment Video
Updated: May 31, 2026
Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
Published on: August 4, 2011
Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities
Lifei Xu1, Bin Wang1, Wenwei Li1
1Department of Ophthalmology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
Abstract:
Retinoblastoma is an early-childhood retinal malignancy driven predominantly by biallelic RB1 inactivation and consequent RB-E2F checkpoint deregulation. Post-translational modifications (PTMs) add a rapid, reversible regulatory layer that rewires RB-centered signaling, chromatin control, metabolic adaptation, and therapy resistance. This review summarizes PTM mechanisms relevant to retinoblastoma, highlighting phosphorylation- and ubiquitination-centric circuits, as well as acetylation and methylation that modulate RB pathway function and downstream oncogenic phenotypes. We discuss actionable therapeutic opportunities, including compounds and degraders targeting PTM enzymes, and emphasize underexplored modifications such as SUMOylation, lactylation, and glycosylation that warrant systematic investigation in retinoblastoma. Finally, we integrate PTM biology with emerging immunotherapies and propose rational PTM-immunotherapy combinations and biomarker-guided translation to improve durable eye salvage and metastatic control.
Insights
Post-translational modifications (PTMs) regulate retinoblastoma (RB) pathway signaling and cancer progression. Targeting these PTMs offers new therapeutic strategies for improved eye salvage and metastatic control.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Retinoblastoma is a childhood eye cancer primarily caused by RB1 gene inactivation.
- Post-translational modifications (PTMs) rapidly alter protein function, influencing cancer signaling pathways.
- RB-centered signaling, chromatin control, metabolism, and therapy resistance are modulated by PTMs.
Purpose of the Study:
- To review PTM mechanisms critical to retinoblastoma pathogenesis.
- To highlight PTM-based therapeutic strategies and underexplored modifications.
- To integrate PTM biology with immunotherapy for enhanced retinoblastoma treatment.
Main Methods:
- Literature review focusing on PTMs in retinoblastoma.
- Analysis of phosphorylation, ubiquitination, acetylation, and methylation circuits.
- Exploration of SUMOylation, lactylation, and glycosylation in RB context.
Main Results:
- PTMs, particularly phosphorylation and ubiquitination, significantly impact RB pathway function.
- Acetylation and methylation modulate RB pathway activity and oncogenic phenotypes.
- Emerging PTMs like SUMOylation, lactylation, and glycosylation require further investigation.
Conclusions:
- Targeting PTM enzymes with compounds or degraders presents viable therapeutic avenues.
- Combining PTM-targeting strategies with immunotherapies may improve treatment outcomes.
- Biomarker-guided translation of PTM research is crucial for durable eye salvage and metastatic control.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:23Negative Regulator Molecules